KaydedilenlerDerginizi ekleyin

Dergiler / European Archives of Medical Research / 2019 / Cilt: 35 - Sayı: 4

Effect of Epidermal Growth Factor on Osteosarcoma Cell Proliferation and Bcl-2 Gene Expression

Ayla Solmaz AVCIKURT
Eren ALTUN
Sayfa
193–196
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The expression of Bcl-2 was increased at the end of the 1st and 24th hours ofapplication of EGF at 20 ng/mL dose.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of this study was to investigate the effects of epidermal growth factor (EGF) on osteosarcoma cell proliferation and Bcl-2 expression.Methods: In this study, MTT test was first applied to determine the effect of EGF on cell proliferation.
📊
Temel Bulgular & Veri:Twenty ng/μL EGF was added to the Saos-2 cell line and the effectson cell proliferation were determined after different incubation intervals.
💡
Sonuç & Katkı:The expression of Bcl-2 was increased at the end of the 1st and 24th hours ofapplication of EGF at 20 ng/mL dose.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The aim of this study was to investigate the effects of epidermal growth factor (EGF) on osteosarcoma cell proliferation and Bcl-2 expression.Methods: In this study, MTT test was first applied to determine the effect of EGF on cell proliferation. Twenty ng/μL EGF was added to the Saos-2 cell line and the effectson cell proliferation were determined after different incubation intervals. At the next experimental stage, 20 ng/mL EGF was added to the osteosarcoma cell line andthe expression of antiapoptotic Bcl-2 was evaluated at 1-, 3-, 24-, 48- and 72-hour.Results: A statistically significant increase in cell proliferation was observed at 3-, 24- and 72-hour after administration of 20 ng/μL EGF in the osteosarcoma cell line.EGF was observed to stimulate Bcl-2 expression at a dose of 20 ng/mL at 1- and 24-hour.Conclusion: EGF; at the 3rd, 24th and 72nd hours, a statistically significant increase in cell proliferation was observed. In addition, the expression of antiapoptotic Bcl-2was evaluated at the 1st, 3rd, 24th, 48th and 72th hours on the EGF osteosarcoma cell line. The expression of Bcl-2 was increased at the end of the 1st and 24th hours ofapplication of EGF at 20 ng/mL dose.

🔖

Bu Makaleye Atıf Yap

AVCIKURT, A. S., ALTUN, E. (2022). Effect of Epidermal Growth Factor on Osteosarcoma Cell Proliferation and Bcl-2 Gene Expression. European Archives of Medical Research, Cilt: 35 - Sayı: 4, 193–196. https://ajindex.com/articles/510459

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Zhang Y, Hu H, Song L, Cai L, Wei R, Jin W. Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation. Toxicol Lett 2013;222:1-9
  2. Liu K, Liu PC, Liu R, Wu X. Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med Sci Monit Basic Res 2015;21:15-20
  3. Su Z, Yang Z, Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer 2015:21;14:48
  4. Taraphdar AK, Roy M, Bhattacharya R. Natural products as inducers of apoptosis: Implication for cancer therapy and prevention. Curr Sci 2001;80:1387-96
  5. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95
  6. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011;30:3667-83
  7. Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, et al. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. Leuk Res 2010;34:166-72
  8. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15:49-63
  9. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factorrelated peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
  10. Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014;51:219-27
  11. Yalçın O, Demir FT, Kılıç AI, Kaya H, Kabukçuoğlu F, Altunay IK. Bcl-2: Is it an Easier Way to Differentiate Psoriasis and Eczema? Okmeydanı Tıp Dergisi 2016;32:190-4
  12. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nature reviews. Cancer 2002;9:647
  13. Sarosiek KA, Letai A. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics–recent successes, current challenges and future promise. FEBS J 2016;283:3523-33
  14. Yarım G F, Kazak F. Epidermal Büyüme Faktörü. Kocatepe Vet J 2016;9:215- 25
  15. Chandra A, Lan S, Zhu J, Siclari VA, Qin L. Epidermal growth factor receptor (EGFR) signaling promotes proliferation and survival in osteoprogenitors by increasing early growth response 2 (EGR2) expression. J Biol Chem 2013;288:20488-98
  16. Guillamo JS, de Boüard S, Valable S, Marteau L, Leuraud P, Marie Y, et al. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on inva